Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1641Carcinoma, Renal Cell 504Urinary Bladder Neoplasms 462Carcinoma, Transitional Cell 234Breast Neoplasms 228Kidney Neoplasms 217Neoplasms 194Carcinoma, Non-Small-Cell Lung 173Colorectal Neoplasms 172Ovarian Neoplasms 163Melanoma 162Neoplasm Metastasis 143Lung Neoplasms 128Non-Muscle Invasive Bladder Neoplasms 107Pancreatic Neoplasms 103Stomach Neoplasms 101Uterine Cervical Neoplasms 93Squamous Cell Carcinoma of Head and Neck 86Endometrial Neoplasms 84Carcinoma, Hepatocellular 77Sarcoma 75Esophageal Neoplasms 72Head and Neck Neoplasms 70Triple Negative Breast Neoplasms 67Adenocarcinoma 66Colonic Neoplasms 53Testicular Neoplasms 52Disease 47Urologic Neoplasms 46Wilms Tumor 45

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Nivolumab 1Leuprolide 1Goserelin 1Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hormone Sensitive Prostate Cancer × Genitourinary × 1 year × Clear all
NCT04126070 2026-05-27

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
47 enrolled 16 charts
Genitourinary

Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡